CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company and its collaborators will present three oral and four poster presentations at the 2015 American Society of Hematology (ASH) Annual Meeting taking place December 5 - 8, 2015 in Orlando, Florida. Collectively, the presentations will focus on the application of FoundationOne® Heme to identify druggable genomic alterations, inform personalized treatment strategies and improve clinical outcomes across a broad range of sarcomas and hematologic malignancies.
FoundationOne Heme is a comprehensive genomic profile that analyzes DNA in 405 genes and RNA in 265 genes that are most commonly altered in hematologic malignancies and sarcomas. The assay provides oncologists and pathologists with clinically relevant genomic alterations to guide treatment options for patients based on the genomic profile of their cancer.
The schedule for oral presentations by Foundation Medicine and/or its collaborators is as follows:
Session Date & Time: Saturday, December 5, 2015, from
12:00-1:30 p.m. ET
Presentation Time: 12:45 p.m. ET
Title:
Genomic and Proteomic Analysis of Primary Chemoresistance and
Induction Failure in Acute Myeloid Leukemia
Publication Number: 88
Location:
Tangerine 3 (WF3-4), Level 2
Session: 617 - Acute
Myeloid Leukemia: Biology, Cytogenetics and Molecular Markers in
Diagnosis and Prognosis: Omics-based Approaches for the Identification
of Novel Genetic Modalities in AML
Presenter: Fiona Brown,
Ph.D., research fellow, Memorial Sloan-Kettering Cancer Center
Collaborators:
Memorial Sloan-Kettering Cancer Center, Dana-Farber Cancer Institute,
Children’s Hospital Boston, Children’s Oncology Group, Fred Hutchinson
Cancer Research Center, The University of Texas MD Anderson Cancer
Center, The Ohio State University Comprehensive Cancer Center, Harvard
Medical School
Session Date & Time: Sunday, December 6, 2015, from 4:30-6:00
p.m. ET
Presentation Time: 5:45 p.m. ET
Title: Comprehensive
Genomic Profiling of Multiple Myeloma in the Course of Clinical Care
Identifies Targetable and Prognostically Significant Genomic Alterations
Publication
Number: 369
Location: W224ABEF
Session: 651
– Myeloma: Biology and Pathophysiology, Excluding Therapy: Novel
Technologies to Evaluate Biology and Prognosis
Presenter: Christopher
Heuck, M.D., assistant professor of medicine, Myeloma Institute for
Research and Therapy, University of Arkansas for Medical Sciences
Collaborators:
Myeloma Institute for Research and Therapy
Session Date & Time: Monday, December 7, 2015 from 7:00-8:30
a.m. ET
Presentation Time: 7:00 a.m. ET
Title: Diverse
and Targetable Kinase Alterations Drive Histiocytic Neoplasms
Publication
Number: 481
Location: W331
Session: 635 –
Myeloproliferative Syndromes: Basic Science I
Presenter: Benjamin
Durham, M.D., research fellow, Memorial Sloan-Kettering Cancer Center
Collaborators:
Memorial Sloan-Kettering Cancer Center
The schedule for poster presentations by Foundation Medicine and/or its collaborators is as follows:
Poster Display: Saturday, December 5, 2015 from 9:00 a.m.-7:30
p.m. ET
Poster Presentation: Saturday, December 5, 2015 from
5:30-7:30 p.m. ET
Title: Integrated DNA/RNA Profiling for
Somatic Alterations in Adult B-cell ALL
Publication Number: 1422
Poster
Display Location: Hall A2-A3
Poster Presentation Location: Hall
A2-A3
Session: 618 – Acute Lymphoblastic Leukemia: Biology,
Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster I
Presenter:
Franck Rapaport, Ph.D., computational research leader, Leukemia
Center, Memorial Sloan-Kettering Cancer Center
Collaborators: Memorial
Sloan-Kettering Cancer Center, Montefiore Medical Center, Mayo Clinic,
University of Pennsylvania, Shaare Zedek Medical Center, Northwestern
University Feinberg School of Medicine, Weill Cornell Medical College
Poster Display: Sunday, December 6, 2015 from 9:00 a.m.-8:00 p.m.
ET
Poster Presentation: Sunday, December 6, 2015 from
6:00-8:00 p.m. ET
Title: Predictive and Prognostic
Significance of Comprehensive Genomic Profiling in Patients with Diffuse
Large B-cell Lymphoma
Publication Number: 2651
Poster
Display Location: Hall A2-A3
Poster Presentation Location: Hall
A2-A3
Session: 622 – Non-Hodgkin Lymphoma: Biology,
Excluding Therapy: Poster II
Presenter: Jie He, senior
manager, computational biology analysis, Foundation Medicine
Poster Display: Sunday, December 6, 2015 from 9:00 a.m.-8:00 p.m.
ET
Poster Presentation: Sunday, December 6, 2015 from
6:00-8:00 p.m. ET
Title: Defining the Incidence and Clinical
Impact of Genomic Alterations Across Different Histologic Types of
Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing
Assay
Publication Number: 2668
Poster Display
Location: Hall A2-A3
Poster Presentation Location: Hall
A2-A3
Session: 622 – Non-Hodgkin Lymphoma: Biology,
Excluding Therapy: Poster III
Presenter: Connie Lee Batlevi,
M.D., Ph.D., hematology/oncology fellow, Memorial Sloan-Kettering Cancer
Center
Collaborators: Memorial Sloan-Kettering Cancer Center
Poster Display: Monday, December 7, 2015 from 10:00 a.m.-8:00
p.m. ET
Poster Presentation: Monday, December 7, 2015 from
6:00-8:00 p.m. ET
Title: Comprehensive Genomic Profiling
(CGP) of Angioimmunoblastic T-cell Lymphoma (AITL) to Prospectively
Inform Diagnosis and Clinical Management
Publication Number: 3898
Poster
Display Location: Hall A2-A3
Poster Presentation Location: Hall
A2-A3
Session: 622 – Non-Hodgkin Lymphoma: Biology,
Excluding Therapy: Poster III
Presenter: Tariq Mughal, M.D.,
vice president, medical affairs, Foundation Medicine
Collaborators:
Memorial Sloan-Kettering Cancer Center, Tufts University Medical
Center
About Foundation Medicine
Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® and FoundationOne® Heme are registered trademarks of Foundation Medicine, Inc.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding presentations by Foundation Medicine and its collaborators of abstracts at American Society of Hematology (ASH) Annual Meeting and the ability of Foundation Medicine's clinical assays to identify genomic alterations, inform the treatment of patients and improve clinical outcomes. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that Foundation Medicine’s clinical assays do not perform in the same manner as the data and information presented at ASH and the risks described under the caption "Risk Factors" in Foundation Medicine's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, which is on file with the Securities and Exchange Commission, as well as other risks detailed in Foundation Medicine's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.
